For example, given the high diagnostic accuracy of the combination of CSF α-synuclein and NfL, these two biomarkers could serve as an initial step to distinguish PSP and CBS from synucleinopathies such as PD, DLB, and MSA. The gene discussed is NEFL; the disease is multiple system atrophy.